Quick Answer
Lumateperone for bipolar depression was FDA-approved in 2021. It's taken once daily, with or without food, at a dose that doesn't require gradual titration. A 2024 network meta-analysis found it had a lower rate of significant weight gain than other approved options, though sleepiness was more common than with placebo.
Understanding lumateperone for Bipolar Depression
Lumateperone is an atypical antipsychotic approved by the FDA for bipolar depression in 2021, making it one of the newest options. A 2024 systematic review and network meta-analysis in European Psychiatry compared the five FDA-approved antipsychotics for bipolar depression: cariprazine, lumateperone, lurasidone, olanzapine-fluoxetine and quetiapine. Across 16 randomized trials with 7,234 patients, it found lumateperone had a lower rate of weight gain of 7% or more than placebo and the other treatments, while lumateperone, olanzapine and quetiapine showed higher odds of sleepiness than placebo. This guide is part of our bipolar care hub for New York adults.
Lumateperone’s dosing is simple. According to a summary of its FDA prescribing information, it’s taken as 42 mg once daily, with or without food, and doesn’t require dose titration. Lower doses are used for people taking certain interacting medications or with moderate to severe liver impairment. Many people take it in the evening because of sleepiness. Simple dosing can make it easier to start and stay consistent. Our guide on cariprazine for bipolar depression covers another once-daily option with a different schedule.
For New Yorkers worried about weight gain on bipolar medication, lumateperone offers a newer option worth discussing. NIMH reports that an estimated 82.9% of adults with bipolar disorder in the past year had serious impairment, the highest share among mood disorders. Secure video visits from anywhere in New York can make it easier to start bipolar care and keep regular follow-ups without extra travel.
How lumateperone is dosed, its weight and sedation profile, and how it compares with approved options are the three topics this guide covers.
Interactions
Lumateperone is processed by the liver enzyme CYP3A4. Strong and moderate inhibitors of this enzyme require lower doses, and strong inducers should be avoided. Tell your prescriber and pharmacist about all medications and supplements. Liver function is also considered when choosing a dose.
Comparing approved options
Each approved option has trade-offs. The 2024 review found cariprazine, lurasidone, olanzapine and quetiapine had higher remission rates than placebo, and olanzapine raised cholesterol and triglycerides. Lumateperone’s strengths include simple dosing and lower weight gain. The right choice depends on your symptoms, health, side effect concerns, interactions and preferences. Your prescriber will compare options with you.
Key Takeaways
- Lumateperone was FDA-approved for bipolar depression in 2021.
- It's taken once daily without a long titration schedule.
- Studies showed lower rates of significant weight gain.
- Sleepiness is a common side effect.
Lumateperone for Bipolar Depression at a glance
| Medication | Notable trait in the review |
|---|---|
| Quetiapine | Higher remission than placebo; more sleepiness |
| Olanzapine-fluoxetine | Higher remission; raised cholesterol and triglycerides |
| Lurasidone | Higher remission than placebo |
| Cariprazine | Higher remission than placebo |
| Lumateperone | Lowest rate of significant weight gain |
Weight and metabolic profile
Weight gain and metabolic changes are major concerns with many bipolar medications. In the 2024 review, lumateperone had the lowest rate of significant weight gain among the approved options. That doesn’t mean metabolic monitoring isn’t needed. Weight, blood sugar and cholesterol are still checked periodically, as with any antipsychotic. For people who’ve struggled with weight gain on other medications, lumateperone may be worth discussing.
Sleepiness
Sleepiness is common with lumateperone. Taking it at bedtime often helps. Some people find the drowsiness eases after the first few weeks. Avoid alcohol and be cautious with driving until you know how it affects you. If daytime sleepiness persists, tell your prescriber, since timing adjustments or alternatives may help. Our guides on cariprazine for bipolar depression and quetiapine sedation and weight gain cover related topics.
Lumateperone care for New York patients
Lumateperone can be prescribed after a secure video evaluation, with prescriptions sent electronically. Visits run by secure video anywhere in New York, while you’re physically in the state. The practice is in-network with Aetna and Cigna; confirm your New York plan with the office, and see self-pay fees on the Good Faith Estimate page.
Monitoring and follow-up
Early follow-ups check mood, sleepiness and other side effects, often every few weeks. Mood charting and PHQ-9 scores help track progress. Like other medications used for bipolar depression, lumateperone carries a warning about suicidal thoughts in younger people, so report mood changes promptly.
When to seek help
Contact your prescriber if sleepiness is hard to tolerate, depression isn’t improving after several weeks or you notice unusual movements. Seek urgent care for high fever with stiff muscles or confusion. Thoughts of suicide need immediate help through 988, and call 911 in an emergency. Lumateperone is one of several approved options for bipolar depression.
People sometimes ask whether newer always means better. Lumateperone has fewer years of real-world use than older options like quetiapine or lithium, so long-term experience is still building. Its studied strengths, simple dosing and lower weight gain, are meaningful for many people. Coverage and cost can also affect the choice, so it’s worth checking your plan. Your prescriber can help you weigh newer and older options together.
The Bottom Line
Lumateperone for Bipolar Depression is common and treatable, and careful care can make daily life feel more manageable.
Frequently Asked Questions
When was lumateperone approved for bipolar depression?
Lumateperone was FDA-approved for bipolar depression in 2021, according to a 2024 review in European Psychiatry. It's one of five antipsychotics approved for bipolar depression. The others are quetiapine, olanzapine-fluoxetine, lurasidone and cariprazine. Each has different trade-offs. Your prescriber can compare them with you. An evaluation can clarify what's happening and which options fit.
How is lumateperone dosed?
According to a summary of its prescribing information, lumateperone is taken as 42 mg once daily. It can be taken with or without food. No gradual titration is required. Lower doses are used with certain interacting medications or liver impairment. Many people take it in the evening.
Does lumateperone cause weight gain?
In a 2024 network meta-analysis, lumateperone had a lower rate of significant weight gain than placebo and other approved treatments. That's a notable strength. Weight, blood sugar and cholesterol are still checked periodically. Individual responses vary for most people. Your prescriber will monitor. An evaluation can clarify what's happening and which options fit.
Does lumateperone make you sleepy?
Yes, sleepiness is common with lumateperone. Taking it at bedtime often helps. Drowsiness may ease after the first few weeks. Avoid alcohol and be cautious with driving until you know how it affects you. Tell your prescriber if daytime sleepiness persists. An evaluation can clarify what's happening and which options fit.
How does lumateperone compare with other bipolar depression medications?
Each approved option has trade-offs. Lumateperone's strengths include simple dosing and lower weight gain in studies. Other options showed higher remission rates than placebo in the 2024 review. The right choice depends on your health, side effect concerns and preferences. Your prescriber will help you decide.
Can lumateperone be prescribed by video in New York?
Yes, lumateperone can be prescribed after a secure video evaluation anywhere in New York. You need to be physically in New York during each visit. Prescriptions go electronically to your pharmacy. The practice is in-network with Aetna and Cigna; confirm your New York plan with the office. Follow-ups track response and side effects.
Where to go from here
- Right now, if you're not safe
- Call or text 988, or call 911.
- If you'd like an evaluation
- See how scheduling and telehealth work on the new patient page.
- If you want to keep reading
- Return to Dr. Farkas's New York bipolar resources for more guides. For more help preparing and finding care, see NIMH’s tips for talking with your health care provider and FindTreatment.gov.
How We Reviewed This Page
Written by Steven Lockhart of Health Marketing Group and clinically reviewed by Gabriella I. Farkas, MD PhD, a board-certified psychiatrist. Clinical information comes from the sources listed below, and the page is reviewed every 180 days or when guidance changes.
What’s new: September 29, 2026. Page published.
References
- Efficacy and tolerability of FDA-approved atypical antipsychotics for bipolar depression: network meta-analysis. European Psychiatry (2024), via PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC10988162/
- PrescriberPoint. Vraylar vs. Caplyta: FDA prescribing information comparison. https://prescriberpoint.com/compare/depression-bipolar/vraylar-4b5f7c6-vs-caplyta-db730b0
- National Institute of Mental Health. Bipolar Disorder statistics. https://www.nimh.nih.gov/health/statistics/bipolar-disorder
- 988 Suicide & Crisis Lifeline. https://988lifeline.org/
- Tips for talking with your health care provider. https://www.nimh.nih.gov/health/publications/tips-for-talking-with-your-health-care-provider
- FindTreatment.gov. https://findtreatment.gov/